Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for
Harness the Maternal-Infant Microbiome, Establish New Mechanisms of Action, and Develop Breakthrough Health Products that Proactively Prevent Disease Risk
Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted.
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas
